BX 513 hydrochloride is a potent and selective inhibitor of TAK1 (TGF-β-activated kinase 1, also known as MAP3K7), primarily used in research settings. It is valuable for studying TAK1-mediated biochemical pathways, such as NF-κB and MAPK signaling, and cellular processes in inflammation, cancer, immune responses, and neurological disorders. Its applications extend to investigating potential therapeutic targets for diseases where TAK1 plays a critical role. Researchers utilize this compound to explore its effects on signaling pathways, helping to identify new drug candidates or mechanisms of action. Additionally, it may be employed in preclinical studies to assess efficacy and safety in disease models, contributing to the development of novel treatments.